Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...

The Urban Prepper demonstrates simple dental hygiene preps for home emergency kits. New details about suspect in murder of Charlie Kirk Trump Says He’s Bringing $15 Billion Lawsuit Against New York ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

US appeals court in Chicago upholds jury verdict, damages Jury found Lilly didn't rebate Medicaid for higher prices Lilly disagrees with decision, plans appeal Sept 11 (Reuters) - A federal appeals ...

Eli Lilly and Co. (NYSE:LLY) on Tuesday launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained ...

FDA's new voucher could shorten drug review to 1-2 months Lilly's orforglipron targets high-burden chronic condition Analysts predict price erosion due to new market entrants Sept 16 (Reuters) - Eli ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk A/S in the first head-to-head ...